Incretin therapy for diabetes mellitus type 2

Research output: Contribution to journal › Review › Research › peer-review

Standard

Incretin therapy for diabetes mellitus type 2. / Holst, Jens Juul.

In: Current Opinion in Endocrinology, Diabetes and Obesity, Vol. 27, No. 1, 2020, p. 2-10.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

Holst, JJ 2020, 'Incretin therapy for diabetes mellitus type 2', Current Opinion in Endocrinology, Diabetes and Obesity, vol. 27, no. 1, pp. 2-10. https://doi.org/10.1097/MED.0000000000000516

APA

Holst, J. J. (2020). Incretin therapy for diabetes mellitus type 2. Current Opinion in Endocrinology, Diabetes and Obesity, 27(1), 2-10. https://doi.org/10.1097/MED.0000000000000516

Vancouver

Holst JJ. Incretin therapy for diabetes mellitus type 2. Current Opinion in Endocrinology, Diabetes and Obesity. 2020;27(1):2-10. https://doi.org/10.1097/MED.0000000000000516

Author

Holst, Jens Juul. / Incretin therapy for diabetes mellitus type 2. In: Current Opinion in Endocrinology, Diabetes and Obesity. 2020 ; Vol. 27, No. 1. pp. 2-10.

Bibtex

@article{0a3b8f65c9f442919f198c0a0c1c3970,
title = "Incretin therapy for diabetes mellitus type 2",
abstract = "Purpose of review Among the gastrointestinal hormones, the incretins: glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 have attracted interest because of their importance for the development and therapy of type 2 diabetes and obesity. New agonists and formulations of particularly the GLP-1 receptor have been developed recently showing great therapeutic efficacy for both diseases. Recent findings The status of the currently available GLP-1 receptor agonists (GLP-1RAs) is described, and their strengths and weaknesses analyzed. Their ability to also reduce cardiovascular and renal risk is described and analysed. The most recent development of orally available agonists and of very potent monomolecular co-agonists for both the GLP-1 and GIP receptor is also discussed. The GLP-1RAs are currently the most efficacious agents for weight loss, and show potential for further efficacy in combination with other food-intake-regulating peptides. Because of their glycemic efficacy and cardiorenal protection, the GLP-1 RAs will be prominent elements in future diabetes therapy.",
keywords = "dulaglutide, glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, semaglutide, weight-losing therapy, GLUCAGON-LIKE PEPTIDE-1, INDUCED INSULIN-SECRETION, GLP-1 RECEPTOR AGONIST, OPEN-LABEL, CARDIOVASCULAR OUTCOMES, ENERGY-INTAKE, IV INHIBITOR, DOUBLE-BLIND, 7-36 AMIDE, GLUCOSE",
author = "Holst, {Jens Juul}",
year = "2020",
doi = "10.1097/MED.0000000000000516",
language = "English",
volume = "27",
pages = "2--10",
journal = "Current Opinion in Endocrinology, Diabetes and Obesity",
issn = "1752-296X",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - Incretin therapy for diabetes mellitus type 2

AU - Holst, Jens Juul

PY - 2020

Y1 - 2020

N2 - Purpose of review Among the gastrointestinal hormones, the incretins: glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 have attracted interest because of their importance for the development and therapy of type 2 diabetes and obesity. New agonists and formulations of particularly the GLP-1 receptor have been developed recently showing great therapeutic efficacy for both diseases. Recent findings The status of the currently available GLP-1 receptor agonists (GLP-1RAs) is described, and their strengths and weaknesses analyzed. Their ability to also reduce cardiovascular and renal risk is described and analysed. The most recent development of orally available agonists and of very potent monomolecular co-agonists for both the GLP-1 and GIP receptor is also discussed. The GLP-1RAs are currently the most efficacious agents for weight loss, and show potential for further efficacy in combination with other food-intake-regulating peptides. Because of their glycemic efficacy and cardiorenal protection, the GLP-1 RAs will be prominent elements in future diabetes therapy.

AB - Purpose of review Among the gastrointestinal hormones, the incretins: glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 have attracted interest because of their importance for the development and therapy of type 2 diabetes and obesity. New agonists and formulations of particularly the GLP-1 receptor have been developed recently showing great therapeutic efficacy for both diseases. Recent findings The status of the currently available GLP-1 receptor agonists (GLP-1RAs) is described, and their strengths and weaknesses analyzed. Their ability to also reduce cardiovascular and renal risk is described and analysed. The most recent development of orally available agonists and of very potent monomolecular co-agonists for both the GLP-1 and GIP receptor is also discussed. The GLP-1RAs are currently the most efficacious agents for weight loss, and show potential for further efficacy in combination with other food-intake-regulating peptides. Because of their glycemic efficacy and cardiorenal protection, the GLP-1 RAs will be prominent elements in future diabetes therapy.

KW - dulaglutide

KW - glucagon-like peptide-1

KW - glucose-dependent insulinotropic polypeptide

KW - semaglutide

KW - weight-losing therapy

KW - GLUCAGON-LIKE PEPTIDE-1

KW - INDUCED INSULIN-SECRETION

KW - GLP-1 RECEPTOR AGONIST

KW - OPEN-LABEL

KW - CARDIOVASCULAR OUTCOMES

KW - ENERGY-INTAKE

KW - IV INHIBITOR

KW - DOUBLE-BLIND

KW - 7-36 AMIDE

KW - GLUCOSE

U2 - 10.1097/MED.0000000000000516

DO - 10.1097/MED.0000000000000516

M3 - Review

C2 - 31815785

VL - 27

SP - 2

EP - 10

JO - Current Opinion in Endocrinology, Diabetes and Obesity

JF - Current Opinion in Endocrinology, Diabetes and Obesity

SN - 1752-296X

IS - 1

ER -

ID: 248460067